BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced that chief executive officer, Craig Thompson, will participate in a fireside chat and host investor meetings at the RBC Capital Markets Healthcare Private Company Conference.

The event will take place virtually from December 13 – 14, 2023 and the fireside chat will be held on Thursday, December 14 from 1:10 – 1:40 pm ET. About CerevanceCerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, prioritizing chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS).

Utilizing a large and growing collection of over 14,000 human brain tissue samples, Cerevance is generating an unprecedented level of expression and epigenetic data thereby enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. The company utilizes its proprietary NETSseq platform and advanced machine learning techniques to uncover the gene expression profiles of select cell types to identify novel targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states.

With the information obtained from its research, combined with the expertise of its team of scientists and drug developers, Cerevance is advancing multiple therapeutics that selectively modulate the discovered targets. These treatments are progressing through clinical development, with CVN424, CVN766, and CVN293 being the furthest along in the pipeline.

CVN424 is a first-in-class non-dopamine therapy that shows promise in improving both motor and non-motor s.